Immunomodulatory drugs, functioning as cereblon (CRBN) E3 ligase ligands, have been approved for treating various hematological malignancies by hijacking the function of CRBN E3 ligase and inducing the degradation of multiple CRBN-associated substrates. However, the inevitable emergence of drug resi...